Genmab — Februar 2016
-
Fra link: We view Genmab / Janssen Biotech’s daratumumab (Darzalex
) as the most exciting new drug approved in 2015 – daratumumab, already granted Breakthrough Designation by the FDA, generated positive Phase II data in double refractory multiple myeloma in February demonstrating an impressive 29.2% overall response rate. The drug was filed with the FDA in July and approved approximately four months later. Darzalex is a major new option for patients and will be one of the key drug launches to f -
Tak Sukker.
-
Gilead får J&J til at sløjfe 14 års samarbejde
Med sin nyeste investering i Galapagos, er Gilead blevet den største aktionær i biotekselskabet, og det får nu Johnson & Johnson til at trække sig helt ud af forretningen.
(medwatch.dk)
-
Det virker som Genmab kommer i et MSCI Denmark Index fra på mandag
-
-
Samtidig ryger Genmab ud af et small cap index
-
-
og Genmab kommer ogsā i MSCI ACWI Growth Index
-
-
Flot slutspurt.
God weekend. -
IBB ser stærk ud + 1,3%
-
-
God morgen. Husk Q&A på onsdag. Vi har plads til mange spørgsmål.:-)
-
Helge, skal man skrive spørgsmålet nu i Q/A rubrikken?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind